Allurion Technologies jumps on initial data from weight-loss device treatment

Healthcare company Allurion Technologies' ALUR.N shares rise 50% to $3.43

Co says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and an increase of lean body mass by 15%

Co's device, Allurion Balloon, occupies space in the stomach and is designed to promote satiety

The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR

Chardan Capital Markets says, "While the path to FDA approval is now more uncertain, we still believe that it is possible the company could still obtain premarket approval based on the benefit/risk"

Brokerage says "a more rigorous randomized controlled study will be needed to further validate the satiety effect of the balloon, leading to increase in lean body mass"

ALUR fell 88.5% in 2024